Ad Scientiam is proud to announce its collaboration with Abata Therapeutics

Ad Scientiam is proud to announce its collaboration with Abata Therapeutics for the first in human clinical trial of ABA-101, an innovative therapy for progressive multiple sclerosis. Thanks to MSCopilot® , we will utilize digital biomarkers related to the disability status, offering valuable support to this pioneering study.

Share